2020
Third quarter 2020 (1 July – 30 September): First nine months 2020 (1 January – 30 September): *) Result per share (DKK...
9 November, 2020
First patient enrolled in the phase I/II clinical trial testing FG001 in patients with high grade glioma
FluoGuide’s phase I/II clinical trial, testing FG001 in patients with high grade glioma consists of two phases; (1) a dose escalation...
26 October, 2020
FluoGuide awarded post doc grant to expand the pipeline
Karina Juhl has been participating in the preclinical experiments supporting development of FG001 for guiding surgery of glioblastoma...
14 October, 2020
FluoGuide A/S presents at BioStock Live
Together with four other Life Science companies, FluoGuide will present at BioStock Live from their studio at Medicon Village in Lund...
21 September, 2020
FluoGuide appoints Henrik Moltke as Chief Financial Officer
FluoGuide wants to strengthen its partnering, financing and other commercial activities to take full advantages of the upcoming results...
FluoGuide appreciates that the Danish Medicines Agency wants to conduct an audit of the clinical trial site at Rigshospitalet to provide...
“The latest development in share price sets the expectations high which we do our outmost to deliver on. I wish to thank our...
FluoGuide’s strategic development plan centers on advancing its lead product, FG001, for targeted glioblastoma surgery, and on...
The preclinical studies needed to support human clinical trials for FG001 have now been completed and reported. The clean outcome of...